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Abstract
Background—Approximately 6% of breast cancers in the United States occur in women under 
the age of 40 years. Compared with women ≥ 40 years of age, younger women are diagnosed at 
later stages, have higher rates of recurrence and death, and may be predisposed to secondary breast 
or ovarian cancer. An informal meeting of experts discussed opportunities for research and public 
health communication related to breast cancer among young (< 40 and/or premenopausal) women.
Methods—In September 2011, the Centers for Disease Control and Prevention hosted 18 experts 
in oncology, genetics, behavioral science, survivorship and advocacy, public health, 
communication, ethics, nutrition, physical activity, and environmental health. They (1) reviewed 
research and programmatic knowledge on risk and preventive factors, early detection, and 
survivorship; and (2) discussed ideas for research, communication, and programmatic efforts 
related to young women diagnosed with or at risk for early onset breast cancer.
Results—Levels of evidence and themes for future research regarding risk and preventive 
factors, including exposures, were discussed. Early detection strategies, including screening, risk 
assessment, and genetic counseling, as well as survivorship issues, follow-up care, fertility and 
reproductive health, and psychosocial care were highlighted.
Conclusion—Community and academic researchers, providers, advocates, and the federal 
public health community discussed strategies and opportunities for this unique population. 
Although the evidence is limited, future research and communication activities may be useful to 
organize future public health initiatives.
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WITH WELL OVER 210,000 new cases occurring every year, breast cancer is the most common 
cancer diagnosis among women in the United States other than non-melanoma skin 
cancer.1,2 Despite significant advances in prevention and treatment, approximately 40,000 
women die each year from breast cancer.2 While the majority of breast cancers are 
diagnosed in women over the age of 50 and often at an early stage,1,2 breast cancer in 
women under 40 raises some unique concerns that have not been well studied.
Young women (under the age of 40 years) account for approximately 5% to 6% of all newly 
diagnosed cases of breast cancer in the United States.2 While it is a rare to be diagnosed 
with breast cancer at a young age, younger women compared to older women (≥ 40 years), 
face higher rates of recurrence and death, are diagnosed at later stages, and have tumors that 
are higher grade and larger in size.2 Also, being diagnosed with breast cancer at a young age 
could be indicative of a genetic mutation making women more susceptible to a secondary 
breast cancer or ovarian cancer.3,4 Additionally, unlike diagnoses among older women with 
breast cancer, African American women under 40 years of age are diagnosed more 
frequently and with more aggressive forms of breast cancer than white women.5 Early 
detection practices, like mammography, are not regularly recommended for women under 40 
years of age.6,7 In addition, these younger women face significant long-term treatment 
related side effects (such as infertility, cognitive dysfunction, muscular and skeletal issues, 
and cardiac and vascular concerns) and an increased risk for several comorbidities.2,4,8-15
In recognition of the need to increase prevention and health promotion research and support 
of this population, the Division of Cancer Prevention and Control (DCPC) at the Centers for 
Disease Control and Prevention (CDC) hosted an informal meeting of recognized experts to 
(a) review published research and programmatic knowledge on risk and preventive factors, 
early detection and survivorship issues related to young women diagnosed with or at risk for 
breast cancer; and (b) discuss areas where the field of public health might have the greatest 
research and communication impact in responding to the needs of this population. The 
objective of this report is to present the key discussion themes and ideas for future research 
and communication efforts discussed during the meeting.
Methods
In September 2011, the CDC/DCPC hosted 18 recognized breast cancer experts in Atlanta, 
Georgia for a 3-day meeting to examine opportunities for research and health 
communication regarding risk and prevention, early detection, and survivorship issues 
related to breast cancer in young women (BCYW; defined as < 40 years of age and/or 
premenopausal).
The participating experts represented government organizations, nongovernmental 
organizations, academic institutions, and recognized community breast cancer advocacy 
organizations. They also represented diverse and unique backgrounds and expertise in the 
following areas: medical oncology, genetics, behavioral science, health psychology, 
oncology nursing, breast cancer survivorship, advocacy, public health, health policy, 
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epidemiology, molecular biology, communication sciences, ethics, nutrition, physical 
activity, and environmental health. Participants were identified based on the number of peer-
reviewed manuscripts they published as a first author since 2000 on topics related to breast 
cancer in young women, their specific area of expertise, and prominence in their area of 
expertise.
A core committee of CDC/DCPC staff, in collaboration with The Cloudburst Consulting 
Group, Inc. (CCG), prepared and reviewed materials (e.g., overview of meeting objectives, 
discussion questions, a review of scientific literature published between January 2000 and 
December 2010) for each participant to consider prior to the meeting. A 1-hour conference 
call with CDC, Strategic Health Concepts, Inc. (SHC) and CCG staff prior to the in-person 
meeting in Atlanta, Georgia was held to answer any questions about the provided materials 
or meeting logistics.
The meeting was facilitated and transcribed by CGG sub-contractors and all meeting 
logistics including; travel and meeting facilities, were arranged by CCG. An ad hoc 
committee of CDC/ DCPC staff served as observers of the meeting and provided 
clarification on CDC related activities.
The first day of the meeting focused on examining existing scientific research gaps 
concerning risk (modifiable and nonmodifiable), prevention, and protective factors for 
breast cancer among young women. For the purposes of this meeting only, participants 
categorized these factors into three categories (those with “strong,” “promising,” or “limited 
or insufficient” scientific evidence) to facilitate the discussion and identified factors for 
public health communication tools and resources. The second day of the meeting focused on 
early detection with a specific emphasis on screening guidelines, genetic counseling and 
testing, provider education, and the identification of high-risk women. The third day of the 
meeting focused on scientific literature and media messages concerning survivorship issues 
and concluded with discussions on social media messaging and communication support 
interventions.
All ideas and suggestions offered regarding risk and prevention, early detection, and 
survivorship issues for breast cancer in younger women were summarized by CCG 
facilitators and participants were given additional time to discuss ideas for future research, 
programmatic and communication efforts at the end of the meeting.
Scientific research gaps: Risk, prevention, and protective factors
To formulate ideas about areas for future research and public health communication, 
participants discussed areas with “strong evidence,” “promising evidence, but not enough 
for significant public health action,” and “limited or insufficient evidence” for modifiable 
risk factors, nonmodifiable risk factors, and protective factors associated with breast cancer 
in young women.
“Strong” evidence—The participants discussed several modifiable and nonmodifiable 
factors and breast cancer risk. The modifiable factors included physical activity, duration of 
breast-feeding, chemoprevention, and alcohol overuse. The nonmodifiable risk factors 
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included, but were not limited to family history (e.g., BRCA1/BRCA genetic mutations), 
age, age at first menarche and onset of puberty, birth characteristics (e.g., birth weight and 
birth order), radiation exposure from previous cancer treatment, breast density, race/
ethnicity (e.g., Ashkenazi Jewish, Hispanic and younger African American women), and 
previous diagnosis and treatment of ovarian, breast, or colon cancer. The classification of 
these factors as “modifiable” versus “nonmodifiable” was varied depending on cultural and 
sociodemographic characteristics: environmental exposures associated with socioeconomic 
status, exposure to second-hand smoke, older age at birth of first child ( ≥ 30 years of age), 
and ever breast-feeding. Panelists had diverse opinions on the strength of the evidence for 
parity and oral contraceptive use as modifiable risk factors.
“Promising” evidence—Several modifiable and nonmodifiable factors were discussed as 
having “promising” evidence, but not enough for significant public health action. While 
participants discussed some of the research linking body mass index (BMI) as a modifiable 
risk factor for breast cancer among premenopausal women depending on age, additional 
knowledge is needed on different racial/ethnic groups in preversus postmenopausal women. 
Another modifiable risk factor that was discussed was the evidence regarding the protective 
qualities of moderate or less than moderate alcohol use in decreasing breast cancer risk 
among premenopausal women. The participants mentioned that nonmodifiable risk factors 
that need additional research include premature birth weight and preterm birth, benign breast 
disease (e.g., atypical hyperplasia), genetic (e.g., BRCA 1/2) and ethnic background factors 
contributing to risk for triple-negative breast cancer, and exposure to pesticides and certain 
other chemicals.
“Insufficient” evidence—The experts discussed several modifiable, nonmodifiable, and 
protective factors for which the evidence is less clear regarding the relationship of each with 
breast cancer in premenopausal women and may be potential areas for future research.
Nutrition, diet, and alcohol consumption—The participants discussed the role of 
organic, vegetarian, and vegan food diets in changing breast cancer risk, the specific type of 
fats (e.g., saturated, unsaturated, polyunsaturated, or monounsaturated) that are protective 
against breast cancer, and the impact of binge drinking on breast cancer risk among young 
women. Despite the potential methodological challenges such as follow-up, retention, and 
accuracy of dietary reporting, participants proposed that a longitudinal study to follow a 
cohort of individuals and document their diets from birth throughout the lifespan may be 
necessary to understand the role of diet in altering the timing of breast development in early 
life.
Reproductive health—Participants stated that examining granddaughters of women 
exposed in utero to diethylstil-bestrol, and the association between fertility drugs and breast 
cancer risk.
Oral contraceptive use—Participants discussed the larger sample sizes of women < 50 
years of age to study the possible link between oral contraceptives as a protective factor for 
premenopausal breast cancer.
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Lactation impairment—Some participants discussed that the current measures of 
insufficient weight gain and death of the infant due to maternal lactation impairment are 
insensitive and have poor end points.
Hair chemicals for African American women—Participants discussed that endocrine 
disruptors, such as hair products with placental extracts, may cause fairly severe premature 
puberty in African American girls as young as four or five years of age. It was noted that 
pubertal progression may stop and reverted back to normal levels if girls discontinued use of 
these products.
Other factors with insufficient evidence—The participants discussed the use of 
tamoxifen, raloxifene, and aromatase inhibitors to decrease breast cancer risk among women 
with a known increased risk for breast cancer; however, it is unclear how these risks vary for 
premenopausal women. Participants stated that the effects of modifiable risk factors like 
environmental and toxin exposures, and stress are considered to have limited evidence for 
premenopausal breast cancer risk. More research is also needed in understanding risk and 
protective qualities of circadian rhythms (e.g., night shift work) and chemoprevention as a 
preventive measure for women at high risk of premenopausal breast cancer.
Public health communication
Knowledge and awareness—Participants offered that communication efforts may 
needed to increase knowledge and awareness among young women who are, or might be, at 
risk for premenopausal breast cancer. Participants discussed that communication efforts 
should be careful not to give women an exaggerated sense of their risk for breast cancer. 
Instead, information should accurately convey the “concepts” of breast cancer risk to the 
public. Women may be educated to (a) know their individual risk, (b) know their family’s 
cancer history and genetic risk, (c) be aware that a women can develop breast cancer even at 
a young age and in the absence of a family history, and (d) be aware that a women can 
develop breast cancer even if a family member tested negative for a genetic mutation. 
Participants also stated that the public health community may need to ensure that 
communication efforts be tailored and clearly defined based on a woman’s level of risk, 
taking special consideration for African American and Ashkenazi Jewish women and those 
with increased genetic risk.
Patient and provider communication—Participants discussed the vast opportunities 
for improving patient and provider communication. Discussions about family history, 
genetic information, and breast cancer risk between providers and patients were suggested 
since they would inform decision-making regarding referral to genetic counseling. 
Educational resource tools may be made available and new applications may be developed 
to help patients and providers estimate patient risk, and primary care providers may need 
education on how to communicate risk factors for premenopausal breast cancer to their 
patients.
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Early detection—Participants discussed the need for improved communication regarding 
screening modalities, screening guidelines, risk assessment tools, and genetic testing 
regarding early detection of breast cancer among young women.
Screening and screening guidelines—The participants mentioned that clear 
information for younger women and the general public about what early detection guidelines 
exist and the similarities between them may be a priority. Participants discussed Magnetic 
Resonance Imaging (MRI) as a method for screening women identified to be at high risk, 
such as BRCA1/2 positive women or women with history of radiation to treat childhood 
cancer, needed further examined. Additionally, participants reported the need for certain 
guidelines to address women with a personal history of breast cancer, women at high risk for 
breast cancer, and women at average risk for breast cancer. These guidelines may emphasize 
the importance of providers understanding delays in diagnosis, the link between awareness 
and delays in diagnosis, and the need for a prompt response to symptoms in the absence of 
screening is recommended. Enhanced physician and patient reminder systems about timing 
of screening were also suggested for young women ( < 40 years).
Risk assessment—Participants discussed the need for a clear definition of “high-risk” 
women before new screening recommendations are developed. Participants acknowledged 
difficulties with determining risk in young women, but without a clear definition, an 
adequate assessment of breast cancer risk conducted by providers could not be done. While 
several participants suggested that providers conduct assessments of their patients to identify 
breast cancer risk beginning at 25 years of age, others suggested that these assessments 
could be performed earlier. One suggestion was to conduct risk assessments during initial 
medical visits and include periodic evaluation of family history and automated risk 
assessment at the time of mammography.
Genetic counseling/testing—Participants discussed that women may need to be 
empowered with ways of gaining access to genetic counseling services. They suggested that 
a centralized resource for providing information on genetic testing be made available to 
individuals and local organizations to find local, competent genetic counselors and centers 
targeting women at high risk for breast cancer. The participants discussed the need for 
provider education for physicians, nurse practitioners, and physician assistants on 
appropriate referral to genetic counseling. They discussed that in order for increased referral 
and uptake of genetic counseling and testing to occur, inconsistencies with insurance 
coverage of genetic counseling and testing may need to be resolved, and increased training 
and licensing of genetic counselors may be necessary to improve service provision.
Survivorship concerns of young breast cancer survivors
Improving follow-up care—Participants stated that there is a dearth of research 
regarding follow-up care for breast cancer survivors under the age of 40 years, and that there 
are currently no guidelines to address the survivorship concerns of this population. 
Participants suggested that organizations involved in cancer care might jointly develop 
survivorship guidelines, which focus on premenopausal women ≤ 40 years of age. They also 
suggested that those who develop survivorship guidelines consider placing a stronger 
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emphasis on patient-centered care and the critical role of nurses and other providers. 
Suggestions on other points to address during the guideline development process were bone 
health and density, lymphedema, weight gain, sexuality and fertility, fatigue, neuropathy, 
weakness, genetic risk, mental health, upper extremity dysfunction, and breast 
reconstruction. Some other suggested guideline topics may be tailored to address various 
effects from different types of tumors and cancer treatment.
In addition to formulating appropriate guidelines for breast cancer survivors under the age of 
40 years, participants also suggested the need for educational resources for providers and 
survivors to increase “good survivorship care” and inform survivors about accessible and 
comprehensive cancer services. Participants discussed that different mechanisms may be 
used to improve patient and provider education, which might include on-demand streaming 
of educational materials, and telemedicine service delivery.
Several suggestions were also offered about ways of improving follow-up care service 
delivery. Participants reported that service delivery mechanisms like telemedicine might be 
used to ensure that providers maintain good communication and to assist survivors in 
achieving access to survivorship services and care plans, particularly in rural areas. 
Participants also stated the widespread publication and dissemination of best practices and 
other published models of survivorship care programs offered in variety of settings and with 
varied resources may be considered. Participants also discussed that existing state-based 
directories of specialists (e.g., lymphedema therapists, certified genetic counselors) and 
other follow-up care information may be organized at the national level to encourage 
national coverage of such directories.
Fertility and reproductive health—Fertility concerns experienced by young women 
with breast cancer were recognized by several participants as a topic of great importance. 
They mentioned that young breast cancer survivors are of reproductive age; treatment and 
care decisions might affect their fertility outcomes. Specifically, fertility issues related to 
recurrence, new cancers, general health perception, general health promotion, treatment, side 
effects, premature aging, and continuity of care may be addressed in the medical care 
context of breast cancer diagnosis and treatment. Participants stated that providers might 
consider addressing fertility issues as part of the survivors’ comprehensive medical 
sequelae. In addition, providers consider having realistic and honest discussions with their 
patients regarding the success rates of Assisted Reproductive Technology (ART) and less 
expensive or alternative options (e.g., gestational surrogacy, adoption).
Participants acknowledged that provider adherence to fertility counseling and treatment 
guidelines may be problematic. They suggested reviewing successful models and lessons 
learned (e.g., adult men with testicular cancer who bank their sperm prior to undergoing 
treatment and specialized care to address the effect of treatment on fertility in male and 
female pediatric and adolescent populations with cancer) to address fertility issues of young 
breast cancer survivors. Participants proposed that recommendations define an appropriate 
time frame for providers to offer referral for reproductive services since women may not be 
sufficiently referred to reproductive endocrinologists prior to initiation of chemotherapy. 
Participants proposed conducting a comprehensive literature review to identify gaps in 
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fertility issues of young women with breast cancer, and to determine the extent to which 
oncologists follow and adopt guidelines. In addition, they discussed that fertility counseling 
and treatment are generally not covered by insurance, which is one of the concerns of young 
breast cancer survivors. Overall, the participants summarized that the lack of insurance 
coverage for fertility treatment has not been adequately addressed to date as a public health 
problem.
Participants stated that culturally tailored education materials and support may be offered to 
husbands and partners, other family members and friends, and young breast cancer survivors 
who may feel uncomfortable in meeting with a reproductive endocrinologist. In addition, 
they discussed that education may be offered to health care providers on issues related to the 
stigma and discrimination among young women with breast cancer who express an interest 
in preserving their fertility, but are unmarried or not in a stable or committed relationship.
Psychosocial care—Emotional, behavioral, and social concerns affecting young breast 
cancer survivors were discussed, and participants stated that the public health community 
may have a vital role in improving upon on several areas of psychosocial health affecting 
young breast cancer survivors. First, participants agreed that clinical practice guidelines for 
psychosocial care of young breast cancer survivors are needed after review of existing 
publications.16,17
Participants discussed that improvement in clinical practice to address psychosocial needs of 
young breast cancer survivors could be made by
(a) conducting psychosocial assessments at the initiation and completion of cancer 
treatment (especially for assessing distress),
(b) ensuring that psychosocial issues specific to young women with breast cancer are 
built into survivorship care plans (e.g., birth control, fertility, early stage in their 
careers, sexual functioning, the financial impact of treatment, premature menopause), 
and
(c) integrating patient navigators and trained health advisors in both community and 
healthcare settings to assist young breast cancer survivors in finding and receiving 
psychosocial services.
Opportunities to partner with community-based organizations, health ministries, and cancer 
ministries in faith-based institutions to address the psychosocial needs of young breast 
cancer survivors were also discussed. Participants suggested that peer counseling and other 
models of community based counseling may be reviewed, because many cancer centers and 
hospitals are not currently staffed to provided adequate psychosocial care to the number of 
survivors that request or need it. Additional suggestions from the participants included 
community based services that may be particularly helpful to those who are low income and 
do not have access to psycho-oncology care due to cost or geographic location. Community-
based programs and organizations are well positioned to disseminate education information 
to providers on the need to address psychosocial issues in their young patients, perform 
baseline assessments, and inform their patients of available resources (e.g., support groups, 
family and partner supportive services). While the need for disseminating information about 
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current resources was broadly discussed, psychosocial supportive services tailored to meet 
the needs of young breast cancer survivors are sparse. Participants stated that comprehensive 
list of available services at regional, state and national levels are needed and may include 
traditional psychological services, peer and family support groups, financial and legal 
services and other important outreach resources that are free or have a reduced cost. 
Providers would optimally give the list of resources to their young breast cancer patients 
during the initial assessment and engage their patients in a follow-up discussions regarding 
available support services at various points across their cancer trajectory (e.g., at the 
conclusion of treatment, during follow-up care).
Lastly, participants discussed that there were several opportunities for additional research on 
the psychosocial needs of young breast cancer survivors. The participants suggested the 
following areas for further exploration:
(a) the role of spirituality in receipt of psychosocial care,
(b) the efficacy and usability of internet-based social networking sites versus traditional 
supportive services, especially for underserved populations,
(c) a systematic review of existing supportive services tailored to meet the needs of 
young breast cancer survivors in ethnic and linguistic minority populations,
(d) the lifelong impact of breast cancer morbidity and mortality on spouses/partners and 
children of younger women, and
(e) the emotional needs of young women who are struggling with decisions and choices 
made regarding fertility and reproductive health.
Conclusions
CDC/DCPC hosted an informal meeting to examine opportunities for breast cancer research 
and health communication surrounding risk and prevention, early detection and survivorship 
for young women. The ideas discussed by these participants provided a strong foundation 
for work underway at CDC to address public health issues related to breast cancer in young 
women. This report describes the expertise offered by subject matter experts for public 
health action, and elucidates future research and communication opportunities.
These participants noted that while there are some risk and protective factors with 
“sufficient” evidence to encourage public health action regarding breast cancer in young 
women, the overall evidence base to support widespread action is still quite limited. This 
provides both opportunities and challenges especially for communicating risk to young 
breast cancer survivors. Likewise, participants noted that early detection for young women 
remains a controversial area in need of further clarification of existing screening guidelines, 
appropriate definitions of risk, accurate risk assessment, and improved access and 
communication about genetic counseling. While several programmatic and research efforts 
are directed at improving the needs of cancer survivors, the participants noted that these 
efforts are not often tailored for young breast cancer survivors, especially for those who 
come from ethnic and linguistic minority populations, and those who are socially and 
economically disadvantaged. The participants suggested that survivorship research and 
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programmatic efforts continue to focus on improving the provision of quality health care and 
recognize opportunities for public health action regarding fertility issues and reproductive 
and psychosocial health.
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